Cenegermin - Dompe Farmaceutici

Drug Profile

Cenegermin - Dompe Farmaceutici

Alternative Names: Nerve growth factor - Anabasis/Dompe; Oxervate; rhNGF; Sentinel

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anabasis Pharma
  • Developer Dompe Farmaceutici; Ospedale San Raffaele
  • Class Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
  • Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Keratitis
  • Phase II Dry eyes; Retinitis pigmentosa
  • Phase I Glaucoma

Most Recent Events

  • 20 Jul 2017 Preregistration for Keratitis in USA (Ophthalmic)
  • 20 Jul 2017 Registered for Keratitis in Liechtenstein, Norway, Iceland (Ophthalmic)
  • 20 Jul 2017 Registered for Keratitis in European Union (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top